SenzaGen strengthens its market presence with expanded distribution channels

SenzaGen has signed agreements with CRO companies GV Research Platform (GVRP) in India and Oroxcell in France for the distribution of the company's non-animal test portfolio, GARD® for chemical risk assessment. These strategic partnerships will enable the broadened distribution of GARD® to key markets driven by regulatory and industrial demand for alternative testing methods.

India is a potentially important and large market where SenzaGen has already noticed increased interest in GARD® and has successfully secured orders from Indian customers. By collaborating with GVRP, a prominent CRO and distribution company in India, SenzaGen now gains access to a robust network and expertise in the country’s thriving Life Science sector.

Similarly, SenzaGen’s partnership with Oroxcell, an well-established CRO in France, strengthens the company’s presence in one of its key geographic markets. France, known for its world-leading companies in cosmetics and pharmaceuticals, has long upheld a ban on animal testing for cosmetics as a member of the EU. With Oroxcell’s strong focus on innovative, animal-free methods, SenzaGen will benefit from their broad network of contacts and specialist knowledge.

”Expanding SenzaGen’s distribution channels is a crucial part of our scaling up as a commercial company. With the addition of two new quality distributors in important markets where we see an increasing demand for GARD®, we are taking important steps on our growth journey,” says Peter Nählstedt, President and CEO of SenzaGen.

Both distributors will actively promote GARD® in their test portfolio, with a focus on biotech, pharma, chemical, and cosmetic companies seeking advanced testing solutions. All tests will be conducted at SenzaGen’s GLP certified laboratory in Lund, Sweden.

About GV Research Platform (GVRP)
Headquartered in Hyderabad, India, GV Research Platform (GVRP) is a pioneering Contract Research Organization focused on providing end-to-end solutions across the drug discovery continuum. Since its establishment in 2020, GVRP has made significant strides towards its vision of enabling efficient and affordable innovation through differentiated and customized R&D solutions. For more information, please visit

About Oroxcell
Oroxcell was founded in 2004. Specialized in efficacy, ADME and toxicity studies for pharmaceutical, cosmetics, nutrition and chemicals products, Oroxcell is a leading CRO company developing alternative methods to animal use. Once validated, these tests are provided as R&D services to its customers. For more information, please visit